# ROADMAP DE MELHORIAS - BRIG IDMP BRASIL

**Vers√£o:** 1.0  
**Data:** 07 de setembro de 2025  
**Horizonte:** 18 meses (v0.0.1 ‚Üí v2.0.0)  
**Status Base:** Prot√≥tipo avan√ßado (85% completo)

---

## VIS√ÉO EXECUTIVA

Este roadmap define o caminho estruturado para evolu√ß√£o do projeto BRIG de prot√≥tipo avan√ßado (v0.0.1) para implementa√ß√£o production-ready (v2.0.0), priorizando conformidade IDMP completa, automa√ß√£o operacional e coordena√ß√£o internacional.

### MARCOS PRINCIPAIS
- **v0.1.0** (1 m√™s): Recursos IDMP cr√≠ticos
- **v0.5.0** (3 meses): Produ√ß√£o MVP  
- **v1.0.0** (6 meses): Produ√ß√£o completa
- **v2.0.0** (18 meses): Lideran√ßa internacional

---

## FASE 1: RECURSOS CR√çTICOS (v0.0.1 ‚Üí v0.1.0)
**Dura√ß√£o:** 4 semanas  
**Objetivo:** Completar recursos IDMP essenciais para funcionalidade b√°sica

### Sprint 1.1: ClinicalUseDefinition (Semanas 1-2)
**Priority:** üî¥ CR√çTICA  
**Esfor√ßo:** 15-20 person-days  
**Owner:** Lead FHIR Developer  

#### Entregas
- [ ] **Profile ClinicalUseDefinition-br** 
  ```fsh
  Profile: ClinicalUseDefinitionBR
  Parent: ClinicalUseDefinition
  Focus: Indica√ß√µes/contraindica√ß√µes brasileiras
  
  Elements:
  - type: indication | contraindication | interaction | warning  
  - subject: Reference(MedicinalProductDefinitionBR)
  - indication.diseaseSymptomProcedure: SNOMED CT + CID-10
  - contraindication: CodeableConcept binding brasileiro
  - interaction.interactant: Reference(SubstanceDefinitionBR)
  ```

- [ ] **ValueSets Brasileiros**
  - `TherapeuticIndicationsBR` (100+ conceitos principais)
  - `ContraindicationsBR` (50+ conceitos)
  - `DrugInteractionTypeBR` (20+ tipos)

- [ ] **Exemplos Funcionais** (3 inst√¢ncias)
  - Dipirona: indica√ß√µes analg√©sica/antipir√©tica
  - Midazolam: contraindica√ß√µes + intera√ß√µes
  - Amoxicilina: indica√ß√µes + contraindica√ß√µes

#### Crit√©rios de Aceita√ß√£o
- ‚úÖ Compila√ß√£o SUSHI sem erros
- ‚úÖ 3 exemplos validados
- ‚úÖ Integra√ß√£o com MedicinalProductDefinition-br
- ‚úÖ Bindings SNOMED CT funcionais

### Sprint 1.2: Extensions e RegulatedAuthorization (Semanas 3-4)
**Priority:** üü° ALTA  
**Esfor√ßo:** 10-15 person-days  

#### Entregas
- [ ] **Reativa√ß√£o Extensions Comentadas**
  ```bash
  Files to fix:
  - input/fsh/examples/*-example.fsh (extensions comentadas)
  - input/fsh/profiles/SubstanceDefinition-br.fsh (linha 150-152)
  ```

- [ ] **Profile RegulatedAuthorization-br**
  ```fsh
  Profile: RegulatedAuthorizationBR
  Parent: RegulatedAuthorization
  Focus: Licen√ßas ANVISA
  
  Elements:
  - identifier: N√∫mero licen√ßa ANVISA
  - type: registration | renewal | variation | suspension
  - holder: Reference(OrganizationANVISA)  
  - regulator: ANVISA (fixed reference)
  - validityPeriod: Per√≠odo validade
  ```

- [ ] **ValueSets Regulat√≥rios**
  - `ANVISAAuthorizationTypeBR`
  - `AuthorizationStatusBR`
  - `VariationTypeBR`

#### Resultados Esperados
- **Conformidade IDMP:** 90% ‚Üí 95%
- **Examples Funcionais:** 8 ‚Üí 12 inst√¢ncias
- **Resources V√°lidos:** 142 ‚Üí 155 recursos

---

## FASE 2: PRODU√á√ÉO MVP (v0.1.0 ‚Üí v0.5.0)  
**Dura√ß√£o:** 8 semanas  
**Objetivo:** Implementa√ß√£o minimamente vi√°vel para ambiente de produ√ß√£o

### Sprint 2.1: Expans√£o Terminol√≥gica (Semanas 5-6)
**Priority:** üî¥ CR√çTICA  
**Esfor√ßo:** 20-25 person-days  

#### Entregas
- [ ] **Expans√£o DCB Brasileiras**
  ```
  Atual: 25 conceitos exemplares
  Meta: 200 conceitos priorit√°rios
  
  Categorias:
  - Cardiovascular: 40 DCBs
  - Antibi√≥ticos: 35 DCBs  
  - Analg√©sicos: 25 DCBs
  - Psiqui√°tricos: 30 DCBs
  - End√≥crinos: 20 DCBs
  - Outros: 50 DCBs
  ```

- [ ] **CodeSystems ANVISA Reais**
  - Substituir placeholders por c√≥digos oficiais
  - Integra√ß√£o com APIs ANVISA (quando dispon√≠vel)
  - Mapeamento ATC ‚Üî DCB

- [ ] **ValueSets de Produ√ß√£o**
  - Embalagens: 50+ tipos oficiais
  - Concentra√ß√µes: unidades farmac√™uticas brasileiras
  - Classifica√ß√µes terap√™uticas expandidas

#### M√©tricas de Sucesso
- **DCB Coverage:** 25 ‚Üí 200+ conceitos
- **ANVISA Codes:** Placeholder ‚Üí Real
- **Binding Coverage:** 85% ‚Üí 95%

### Sprint 2.2: Automa√ß√£o e Testing (Semanas 7-8)
**Priority:** üü° ALTA  
**Esfor√ßo:** 15-20 person-days  

#### Entregas
- [ ] **Pipeline CI/CD**
  ```yaml
  GitHub Actions Workflow:
  - SUSHI compilation
  - FHIR validation  
  - IG generation
  - Quality gates
  - Automated deployment
  ```

- [ ] **Test Suite Abrangente**
  ```
  Test Categories:
  - Unit tests: Profile validation
  - Integration tests: Cross-reference validation
  - Example tests: All instances validate
  - Terminology tests: Binding validation
  - Performance tests: Compilation time
  ```

- [ ] **Quality Dashboard**
  - M√©tricas de conformidade FHIR
  - Coverage terminol√≥gico
  - Performance de compila√ß√£o
  - Status de depend√™ncias

### Sprint 2.3: Documenta√ß√£o Usu√°rio Final (Semanas 9-10)
**Priority:** üü¢ M√âDIA  
**Esfor√ßo:** 10-12 person-days  

#### Entregas
- [ ] **Implementation Guide Completo**
  - Guia de instala√ß√£o passo-a-passo
  - Tutorial de uso b√°sico
  - Exemplos pr√°ticos comentados
  - FAQ t√©cnico

- [ ] **Developer Documentation**
  - API reference (se aplic√°vel)
  - Extension development guide
  - Contribution guidelines
  - Architecture decisions

- [ ] **User Guides**
  - Guia para implementadores
  - Guia para farmac√™uticos
  - Guia para reguladores ANVISA

### Sprint 2.4: Integra√ß√£o e Valida√ß√£o (Semanas 11-12)
**Priority:** üî¥ CR√çTICA  
**Esfor√ßo:** 15-18 person-days  

#### Entregas
- [ ] **Valida√ß√£o com Dados Reais**
  - 50 produtos medicinais reais ANVISA
  - Valida√ß√£o contra base dados oficial
  - Performance com volume realista

- [ ] **Corre√ß√£o Limita√ß√µes Tempor√°rias**
  - Remover limite recurs√£o PackagedProductDefinition
  - Otimizar estruturas complexas
  - Validar hierarquias de embalagem

#### Crit√©rios v0.5.0 MVP
- ‚úÖ Zero erros compila√ß√£o com dados reais
- ‚úÖ Performance < 5min para 1000 recursos
- ‚úÖ Documenta√ß√£o completa usu√°rio final
- ‚úÖ Pipeline automatizado funcionando

---

## FASE 3: PRODU√á√ÉO COMPLETA (v0.5.0 ‚Üí v1.0.0)
**Dura√ß√£o:** 12 semanas  
**Objetivo:** Implementa√ß√£o production-ready com recursos avan√ßados

### Sprint 3.1: Recursos IDMP Avan√ßados (Semanas 13-15)
**Priority:** üü° ALTA  
**Esfor√ßo:** 20-25 person-days  

#### Entregas
- [ ] **AdministrableProductDefinition-br Completo**
  ```fsh
  Expansions:
  - Formas administr√°veis complexas
  - Dispositivos de administra√ß√£o
  - Instru√ß√µes de uso detalhadas
  - Propriedades f√≠sico-qu√≠micas
  ```

- [ ] **ManufacturedItemDefinition-br Avan√ßado**
  ```fsh
  New Features:
  - Especifica√ß√µes de manufatura
  - Controle de qualidade
  - Batch/lot tracking
  - Certifica√ß√µes GMP
  ```

- [ ] **Ingredient-br Especializado**
  ```fsh
  Advanced Features:
  - Concentra√ß√µes complexas (multi-step)
  - Reference strengths
  - Impurities tracking
  - Stability data
  ```

### Sprint 3.2: Casos de Uso Complexos (Semanas 16-18)
**Priority:** üü¢ M√âDIA  
**Esfor√ßo:** 18-22 person-days  

#### Entregas
- [ ] **Produtos Biol√≥gicos**
  ```fsh
  Support for:
  - Vacinas (multi-strain)
  - Hemoderivados
  - Biosimilares
  - Terapias celulares
  ```

- [ ] **Produtos Combinados**
  ```fsh
  Complex Products:
  - Fixed-dose combinations
  - Device-drug combinations
  - Diagnostic combinations
  - Kit products  
  ```

- [ ] **Embalagens Hospitalares**
  ```fsh
  Hospital Packaging:
  - Bulk containers
  - Unit-dose packaging
  - Sterile packaging
  - Multi-use vials
  ```

### Sprint 3.3: Conformidade Avan√ßada (Semanas 19-21)
**Priority:** üü° ALTA  
**Esfor√ßo:** 15-18 person-days  

#### Entregas
- [ ] **Auditoria Conformidade Completa**
  - ISO 11615: 100% compliance check
  - FHIR R5: Deep conformance validation
  - ANVISA: Regulatory alignment audit

- [ ] **Performance Optimization**
  ```
  Targets:
  - Compilation: < 2min for 5000 resources
  - Memory usage: < 4GB during build  
  - Storage: < 100MB for complete IG
  ```

- [ ] **Security Hardening**
  - Vulnerability scanning
  - Dependency security check
  - Data privacy compliance (LGPD)

### Sprint 3.4: Production Deployment (Semanas 22-24)
**Priority:** üî¥ CR√çTICA  
**Esfor√ßo:** 12-15 person-days  

#### Entregas
- [ ] **Production Infrastructure**
  ```yaml
  Environment Setup:
  - Production CI/CD pipeline
  - Monitoring and alerting  
  - Backup and recovery
  - High availability setup
  ```

- [ ] **Operations Procedures**
  - Release management process
  - Change management workflow
  - Incident response procedures
  - Maintenance schedules

#### v1.0.0 Production Criteria
- ‚úÖ 100% IDMP conformance
- ‚úÖ < 2min build time for full IG
- ‚úÖ Zero critical security vulnerabilities
- ‚úÖ Complete operational procedures

---

## FASE 4: LIDERAN√áA INTERNACIONAL (v1.0.0 ‚Üí v2.0.0)  
**Dura√ß√£o:** 12 meses  
**Objetivo:** Posicionamento como refer√™ncia global IDMP

### Milestone 4.1: Coordena√ß√£o UMC/OMS (Meses 7-9)
**Priority:** üü¢ BAIXA (n√£o bloqueia nacional)  
**Esfor√ßo:** 30-40 person-days distribu√≠dos  

#### Entregas
- [ ] **Estabelecimento Canal UMC**
  - Contato formal Uppsala Monitoring Centre
  - Participa√ß√£o reuni√µes IDMP internacional
  - Representa√ß√£o brasileira em grupos de trabalho

- [ ] **PHPID Implementation Strategy**
  ```fsh
  PHPID Coordination:
  - Global identifier namespace
  - Harmonization with other countries
  - Integration roadmap
  - Governance participation
  ```

- [ ] **International Alignment**
  - Cross-IG compatibility testing
  - Harmonization workshops
  - Best practices sharing

### Milestone 4.2: Expans√£o Regional (Meses 10-12)
**Priority:** üü¢ M√âDIA  
**Esfor√ßo:** 25-30 person-days  

#### Entregas
- [ ] **Latin America Leadership**
  - BRIG as reference for region
  - Technical cooperation agreements
  - Training programs for other countries

- [ ] **Multilingual Support**
  ```fsh
  Language Extensions:
  - Spanish translations (key ValueSets)
  - English documentation
  - International examples
  ```

### Milestone 4.3: Advanced Features (Meses 13-18)
**Priority:** üü¢ BAIXA  
**Esfor√ßo:** 40-50 person-days  

#### Entregas
- [ ] **AI/ML Integration**
  - Automated terminology mapping
  - Quality prediction models
  - Anomaly detection

- [ ] **Advanced Analytics**
  - Usage patterns analysis
  - Performance dashboards
  - Compliance reporting

- [ ] **Ecosystem Integration**
  - EHR systems integration
  - Pharmacy management systems
  - Regulatory submission systems

---

## CRONOGRAMA CONSOLIDADO

### Timeline Visual
```
2025 Sep |‚ñà‚ñà‚ñà‚ñà| v0.1.0 - Critical Resources
2025 Nov |‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| v0.5.0 - Production MVP  
2026 Feb |‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| v1.0.0 - Production Complete
2026 Aug |‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| v1.5.0 - International Coordination
2027 Mar |‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| v2.0.0 - Global Leadership
```

### Marcos Detalhados
| Milestone | Data | Funcionalidades Principais |
|-----------|------|------------------------------|
| **v0.1.0** | Out 2025 | ClinicalUse + RegulatedAuth |
| **v0.2.0** | Nov 2025 | DCB expandida + Automa√ß√£o |
| **v0.5.0** | Dez 2025 | Production MVP ready |
| **v0.8.0** | Jan 2026 | Advanced IDMP features |
| **v1.0.0** | Fev 2026 | Production complete |
| **v1.5.0** | Ago 2026 | International coordination |
| **v2.0.0** | Mar 2027 | Global leadership |

---

## RECURSOS E INVESTMENT

### Equipe Recomendada

#### Core Team (v0.1.0 ‚Üí v1.0.0)
```
Lead FHIR Developer (1.0 FTE)
- FHIR R5 expertise
- FSH/SUSHI proficiency  
- IDMP knowledge

Terminology Specialist (0.5 FTE)
- SNOMED CT experience
- Healthcare coding
- Brazilian regulatory knowledge

DevOps Engineer (0.3 FTE)
- CI/CD pipeline setup
- Infrastructure automation
- Monitoring/alerting

Technical Writer (0.3 FTE)
- IG documentation
- User guides
- API documentation
```

#### Extended Team (v1.0.0 ‚Üí v2.0.0)
```
International Coordinator (0.2 FTE)
- UMC/OMS liaison
- Global standards participation
- Multi-country coordination

Quality Assurance (0.3 FTE)
- Testing automation
- Compliance validation
- Performance testing

Business Analyst (0.2 FTE)
- Requirements gathering
- Stakeholder management
- Process optimization
```

### Budget Estimado (18 meses)

#### Personnel (80% do budget)
```
Core Team (6 meses):      R$ 450.000
Extended Team (12 meses): R$ 600.000
Consultoria (ad-hoc):     R$ 100.000
Total Personnel:          R$ 1.150.000
```

#### Infrastructure & Tools (20% do budget)
```
Cloud Infrastructure:     R$ 60.000
Development Tools:        R$ 40.000
Conferences/Travel:       R$ 80.000
Training/Certification:   R$ 50.000
Contingency (10%):        R$ 87.000
Total Non-Personnel:      R$ 287.000
```

#### **Total Investment: R$ 1.437.000**

---

## RISCOS E MITIGA√á√ïES

### Riscos T√©cnicos

#### Alto: Complexidade PHPID Internacional
```
Risk: Coordena√ß√£o UMC/OMS mais demorada que esperado
Impact: Atraso v1.5.0/v2.0.0 (n√£o bloqueia v1.0.0)
Probability: 60%

Mitigation Strategy:
- MPID/PCID independentes de PHPID ‚úÖ
- Sistema placeholder robusto ‚úÖ  
- Cronograma flex√≠vel para coordena√ß√£o ‚úÖ
- Foco em valor nacional primeiro ‚úÖ
```

#### M√©dio: Expans√£o Terminol√≥gica
```
Risk: DCB expansion mais trabalhosa que estimado
Impact: Atraso v0.5.0, funcionalidade reduzida
Probability: 40%

Mitigation Strategy:
- Prioriza√ß√£o por categoria terap√™utica
- Automa√ß√£o parcial via APIs ANVISA
- Processo incremental bem definido
- Fallback para core DCBs essenciais
```

### Riscos Organizacionais

#### M√©dio: Disponibilidade Recursos
```
Risk: Equipe especializada dif√≠cil de recrutar/manter
Impact: Atrasos generalizados, qualidade reduzida  
Probability: 50%

Mitigation Strategy:
- Contratos competitivos para especialistas
- Training program para desenvolvimento interno
- Consultoria externa para knowledge transfer
- Documenta√ß√£o t√©cnica robusta
```

#### Baixo: Mudan√ßas Regulat√≥rias
```
Risk: Altera√ß√µes ANVISA impactam requirements
Impact: Retrabalho parcial, ajustes menores
Probability: 30%

Mitigation Strategy:
- Arquitetura extens√≠vel e modular ‚úÖ
- Relacionamento pr√≥ximo com ANVISA
- Processo de change management definido
- Versionamento sem√¢ntico rigoroso
```

---

## M√âTRICAS E KPIs

### M√©tricas T√©cnicas

#### Qualidade de C√≥digo
```
FHIR Conformance Score: Target 98%+ (atual 95%)
Compilation Success Rate: Target 100% (atual 100%)
Test Coverage: Target 90%+ (atual manual)
Performance: Target <2min build (atual ~5min)
```

#### Funcionalidade
```
IDMP Conformance: Target 98%+ (atual 85%)
Profile Completeness: Target 100% (atual 85%)
Example Coverage: Target 95%+ (atual 70%)
Documentation Coverage: Target 95%+ (atual 90%)
```

### M√©tricas de Neg√≥cio

#### Ado√ß√£o
```
Community Engagement: Target 50+ contributors
Download/Usage Stats: Target 1000+ monthly
Implementation Partners: Target 10+ organizations
International Recognition: Target 3+ countries interested
```

#### Impacto
```
ANVISA Process Efficiency: Target 30% improvement
Industry Standardization: Target 80% adoption in 3 years
International Leadership: Top 3 IDMP implementations globally
Academic Citations: Target 20+ papers referencing BRIG
```

---

## CRIT√âRIOS DE SUCESSO

### v0.1.0 Success Criteria
- [ ] ClinicalUseDefinition-br implemented and tested
- [ ] RegulatedAuthorization-br functional
- [ ] Zero compilation errors with expanded resources
- [ ] 95%+ IDMP conformance achieved

### v0.5.0 Success Criteria  
- [ ] 200+ DCB concepts implemented
- [ ] Automated CI/CD pipeline operational
- [ ] Production-grade performance (<5min build)
- [ ] Complete user documentation published

### v1.0.0 Success Criteria
- [ ] 98%+ FHIR R5 conformance
- [ ] 100% core IDMP features implemented
- [ ] Production deployment successful
- [ ] Zero critical security vulnerabilities

### v2.0.0 Success Criteria
- [ ] PHPID coordination established
- [ ] Regional leadership position secured
- [ ] International recognition achieved
- [ ] Advanced features operational

---

## COMUNICA√á√ÉO E STAKEHOLDERS

### Internal Stakeholders
- **Product Owner:** Strategic decisions, resource allocation
- **Development Team:** Technical implementation, quality
- **QA Team:** Testing, validation, compliance
- **DevOps Team:** Infrastructure, automation, deployment

### External Stakeholders
- **ANVISA:** Regulatory alignment, feedback, adoption
- **Pharmaceutical Industry:** Requirements, pilot testing
- **Healthcare Providers:** Use cases, integration needs
- **Academic Community:** Research collaboration, validation

### Communication Plan
```
Weekly: Development team standups
Bi-weekly: Stakeholder progress reports  
Monthly: ANVISA alignment meetings
Quarterly: International community updates
Major Releases: Public announcements, conferences
```

---

## CONCLUS√ÉO

Este roadmap estabelece caminho claro e estruturado para evolu√ß√£o do BRIG de prot√≥tipo avan√ßado para implementa√ß√£o de lideran√ßa internacional. O cronograma de 18 meses √© ambicioso mas realiz√°vel com recursos adequados e execu√ß√£o disciplinada.

### Pr√≥ximos Passos Imediatos
1. **Aprova√ß√£o Executive** do roadmap e budget
2. **Recrutamento Core Team** (Lead FHIR Developer priority)
3. **Setup Infrastructure** (reposit√≥rio, CI/CD b√°sico)  
4. **Kickoff Sprint 1.1** (ClinicalUseDefinition)

### Fatores Cr√≠ticos de Sucesso
- **Qualidade T√©cnica:** Manter padr√µes excepcionais atuais
- **Foco Stakeholder:** Priorizar valor para ANVISA/Industry
- **Execu√ß√£o Disciplinada:** Seguir cronograma e entregas
- **Vis√£o Internacional:** Preparar para lideran√ßa global

O projeto BRIG tem potencial √∫nico para posicionar o Brasil como l√≠der global em implementa√ß√£o IDMP, com benef√≠cios significativos para ecossistema farmac√™utico nacional e proje√ß√£o internacional.

---

**Roadmap aprovado:** [ ] Aguardando aprova√ß√£o  
**Start date:** Outubro 2025 (estimado)  
**Budget approved:** [ ] Aguardando aprova√ß√£o or√ßament√°ria  

*Documento elaborado por Assistente T√©cnico Especializado*  
*Vers√£o 1.0 - 07/09/2025*